전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-1 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 1

atezolizumab (Tecentriq, carbplatin, cyclophophamide, atezolizumab)

Breast Cancer; Cervix Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#monoclonal-antibody#CervixCancer+1
Trials 1Status Active
AntibodyLimited DatastaleShanghai Zhongshan HospitalPhase 2

cardonilizumab (cardonilizumab)

Biliary Tract Cancer; Candonilimab · Biliary Tract Cancer

#BiliaryTractCancer#Antibody#Phase2#monoclonal-antibody#Candonilimab+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

KDD (carfilzomib/daratumumab/dexamethasone, carfilzomib/daratumumab/dexamethasone (KDD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Janssen
Trials 1Status Discontinued
AntibodyLimited DatastaleEli LillyPhase 2

cisplatin, vinorlebine, cetuximab (cisplatin, vinorlebine, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatine, etoposide, cetuximab (cisplatine, etoposide, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

cixutumumab (cixutumumab)

Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer

#RecurrentNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#StageIIIBNon-smallCellLungCancer+1
Trials 1Status Active
AntibodyLimited DatastaleJanssenApproved

daclizumab, infliximab (daclizumab, infliximab)

Graft vs Host Disease · Graft vs Host Disease

#GraftvsHostDisease#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Active
AntibodyLimited DatastaleSaglik Bilimleri UniversitesiPreclinical

ranibizumab (Lucentis, dexamethasone implant versus ranibizumab)

Diabetic Macular Edema; Inflammation · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Inflammation+1
Trials 1Status Active
CGTLimited DatastaleYuLiPhase 2

dual target CAR-T cell therapy (dual target CAR-T cell therapy)

Lymphoma, B-Cell; Relapse/Recurrence · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleStanford UniversityPhase 1

dupliumab (dupliumab)

Eosinophilic Disorder; Food Allergy · Eosinophilic Disorder

#EosinophilicDisorder#Antibody#Phase1#monoclonal-antibody#FoodAllergy+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRocheApproved

eltrombopag combining rituximab (eltrombopag combining rituximab)

Primary Immune Thrombocytopenia (ITP) · Primary Immune Thrombocytopenia (ITP)

#PrimaryImmuneThrombocytopeniaITP#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Recruiting
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active
ADCLimited DatastaleDaiichi SankyoPhase 2

T-DXd (fam-trastuzumab deruxtecan-nxki, fam-trastuzumab deruxtecan-nxki (T-DXd))

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleGlaxoSmithKlinePhase 1

GSK3359609 (feladilimab, feladilimab (GSK3359609))

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase1#monoclonal-antibody#GlaxoSmithKline
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

fetal MSCs combined with 4SCAR T cells (fetal MSCs combined with 4SCAR T cells)

Autoimmune Diseases · Autoimmune Diseases

#AutoimmuneDiseases#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine and rituximab (fludarabine and rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine, rituximab, pixantrone (fludarabine, rituximab, pixantrone)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleEli LillyPhase 2

fulzerasib; cetuximab N01 (fulzerasib; cetuximab N01)

Colorectal Cancer; KRAS G12C Mutant Advanced Solid Tumors · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#KRASG12CMutantAdvancedSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

gemcitabine + cetuximab (gemcitabine + cetuximab)

Time to Progression · Time to Progression

#TimetoProgression#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastalePfizerPhase 3

gemtuzumab ozogamycin (gemtuzumab ozogamycin)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase3#monoclonal-antibody#Pfizer
Trials 1Status Active

97 / 103 pages

← PreviousNext →